Collaboration on inflammasome modulators

Inflammasomes are large multiprotein complexes which assemble in a cell’s cytoplasm in response to environmental danger signals and are considered an essential part of an organism’s innate immune response. Activation of an inflammasome assembly leads to the release of pro-inflammatory cytokines, IL-1 and IL-18. Over-activation of the NRLP3 inflammasome is implicated in a wide range of diseases that are a substantial burden on modern healthcare systems such as type 2 diabetes, gout, rheumatoid arthritis, Alzheimer’s disease and cancer. Until recently, the NLRP3 inflammasome has been a difficult target. However, recent advances and insights from the scientific community has renewed and re-invigorated interest in targeting the NLRP3 inflammasome. Selective inhibition of the NLRP3 inflammasome rather than its downstream cytokines holds great therapeutic potential.

The project is developed in collaboration with Nodthera Limited, a biotech company focused on the discovery and development of novel inhibitors of the NLRP3 inflammasome. Nodthera Ltd. was launched in July 2016 by Epidarex Capital, and is based on world class research conducted within Selvita S.A.